LAPTM4B and colorectal carcinoma: In colorectal carcinoma, patients with high LAPTM4B-35 expression had a worse OS and DFS17.In non-small-cell lung cancer, LAPTM4B-35 overexpression was associated with significantly worse 5-year OS and progression free survival34.